You are here

Company Pulls Plug on Investigational RA Drug

CRP-targeting agent is no better than placebo (August 5)

In a new phase II study, patients with rheumatoid arthritis (RA) and chronically elevated C-reactive protein (CRP) levels achieved dose-dependent mean reductions of up to 67% in CRP after treatment with an experimental RA drug, ISIS-CRPRx. However, even though these patients showed improvements in the signs and symptoms of the disease, the improvements were not statistically significant compared with those observed in patients given placebo.

According to the drug’s developer (Isis Pharmaceutcials), the study results do not justify further development of ISIS-CRPRx for the treatment of RA.

The drug was developed using so-called “antisense” technology, which helps a compound bind to a specific gene in order to interrupt the production of disease-causing proteins.

In January, Isis Pharmaceuticals received FDA approval for Kynamro (mipomersen sodium), which uses the same technology to treat patients with homozygous familial hypercholesterolemia, a rare genetic disorder causing dangerously high levels of “bad” low-density lipoprotein (LDL) cholesterol.

A phase II study is currently evaluating ISIS-CRPRx in patients with atrial fibrillation, with data expected in the first half of 2014.

Sources: Isis Pharmaceuticals; August 5, 2013; and Reuters; August 5, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress